
NuVasive NUVA
Quarterly report 2023-Q2
added 08-02-2023
NuVasive General and Administrative Expenses 2011-2026 | NUVA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses NuVasive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 634 M | 610 M | 547 M | 611 M | 576 M | 540 M | 534 M | 465 M | 470 M | 420 M | 372 M | 347 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 634 M | 347 M | 510 M |
Quarterly General and Administrative Expenses NuVasive
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 164 M | 176 M | - | 154 M | 161 M | 160 M | - | 146 M | 157 M | 146 M | - | 146 M | 126 M | 130 M | - | 153 M | 153 M | 145 M | - | 141 M | 146 M | 147 M | - | 126 M | 139 M | 140 M | - | 132 M | 134 M | 125 M | - | 111 M | 115 M | 116 M | - | 114 M | 117 M | 118 M | - | 102 M | 104 M | 99.9 M | - | 87.4 M | 92.6 M | 94.7 M | - | 85.5 M | 84.3 M | 84.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 176 M | 84.2 M | 128 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
45.8 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.43 | -3.3 % | $ 324 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 7.77 | -3.6 % | $ 1.17 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
14.1 M | $ 4.13 | -4.18 % | $ 155 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.24 | -2.61 % | $ 49.4 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.04 | - | $ 17.6 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.48 | 4.37 % | $ 29.9 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 17.52 | -2.15 % | $ 411 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 10.93 | 0.92 % | $ 392 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
LENSAR
LNSR
|
45.2 M | $ 5.92 | -2.15 % | $ 70.8 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.54 | -1.98 % | $ 62.7 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 73.61 | -2.39 % | $ 4.02 B | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Myomo
MYO
|
14 M | $ 0.99 | -3.64 % | $ 41.4 M | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.59 | -2.32 % | $ 531 M | ||
|
Electromed
ELMD
|
39.3 M | $ 37.81 | -0.97 % | $ 320 M | ||
|
Butterfly Network
BFLY
|
39.2 M | $ 4.54 | -0.22 % | $ 1.12 B | ||
|
Orthofix Medical
OFIX
|
554 M | $ 9.35 | -4.3 % | $ 370 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Profound Medical Corp.
PROF
|
32.1 M | $ 6.9 | 1.92 % | $ 209 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 82.74 | -2.74 % | $ 11.2 B | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 144.76 | -5.88 % | $ 10.2 B | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.36 | -2.88 % | $ 6.55 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 35.57 | -1.36 % | $ 1.1 B | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 41.71 | -0.88 % | $ 1.22 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 88.62 | -1.61 % | $ 3.08 B | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 86.49 | -1.2 % | $ 50.6 B | ||
|
TransMedics Group
TMDX
|
185 M | $ 69.31 | -1.63 % | $ 2.36 B |